Department of Clinical and Experimental Medicine, University of Foggia, Via Pinto 1, 71122 Foggia, Italy.
Department of Medical and Surgical Sciences, University of Foggia, Via Pinto 1, 71122 Foggia, Italy.
Int J Mol Sci. 2023 May 16;24(10):8824. doi: 10.3390/ijms24108824.
Luteolin (3',4',5,7-tetrahydroxyflavone), a member of the flavonoid family derived from plants and fruits, shows a wide range of biomedical applications. In fact, due to its anti-inflammatory, antioxidant and immunomodulatory activities, Asian medicine has been using luteolin for centuries to treat several human diseases, including arthritis, rheumatism, hypertension, neurodegenerative disorders and various infections. Of note, luteolin displays many anti-cancer/anti-metastatic properties. Thus, the purpose of this review consists in highlighting the relevant mechanisms by which luteolin inhibits tumor progression in metastasis, i.e., affecting epithelial-mesenchymal transition (EMT), repressing angiogenesis and lysis of extracellular matrix (ECM), as well as inducing apoptosis.
木樨草素(3',4',5,7-四羟基黄酮),一种源自植物和水果的类黄酮家族成员,具有广泛的生物医学应用。事实上,由于其抗炎、抗氧化和免疫调节活性,亚洲医学几个世纪以来一直使用木樨草素来治疗多种人类疾病,包括关节炎、风湿病、高血压、神经退行性疾病和各种感染。值得注意的是,木樨草素显示出许多抗癌/抗转移特性。因此,本综述的目的在于强调木樨草素抑制转移中肿瘤进展的相关机制,即影响上皮-间充质转化(EMT)、抑制血管生成和细胞外基质(ECM)的溶解,以及诱导细胞凋亡。
Curr Cancer Drug Targets. 2008-11
Biomed Pharmacother. 2019-2-21
Int J Mol Sci. 2023-1-21
Int J Mol Sci. 2023-11-6
Molecules. 2008-10-22
Mater Today Bio. 2025-6-7
Front Pharmacol. 2025-3-3
Pharmaceuticals (Basel). 2025-1-22
Int J Mol Sci. 2025-1-27
Cancer Control. 2024
Front Microbiol. 2023-11-14
Cancer Metastasis Rev. 2023-3
Int J Mol Sci. 2023-2-15
Cancer Cell Int. 2022-12-8
Cancers (Basel). 2022-10-31